Hoth Therapeutics, Inc.
Small molecule therapeutics for rare and orphan diseases
- Sector
- Biotech
- Headquarters
- NEW YORK, NY
- Founded
- 2017
- Latest Form D
- $10M, Jan 2023
- Total capital
- $33.7M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $33.7M
- 6 Form D · last Jan 2023
- 46 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 14 pending · first 2024
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 6th filing$10M
- Private capital raisedForm D · SEC · 5th filing$15M
- Private capital raisedForm D · SEC · 4th filing$5M
- Private capital raisedForm D · SEC · 3rd filing$2M
- Private capital raisedForm D · SEC · 2nd filing$1M
- Private capital raisedForm D · SEC · 1st filing$675K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- ROBB KNIEResearcherExecutive Officer, PromoterLinked by 1 patent
- Anthony HayesDirectorNamed in SEC Form D filings
- David BrionesExecutive OfficerNamed in SEC Form D filings
- David SarnoffDirectorNamed in SEC Form D filings
- Graig SpringerDirectorNamed in SEC Form D filings
- Jeff PavellDirectorNamed in SEC Form D filings
Show all 10 people
- KENNETH RICEDirectorNamed in SEC Form D filings
- Stefanie JohnsExecutive OfficerNamed in SEC Form D filings
- VADIM MATSDirectorNamed in SEC Form D filings
- Wayne LinsleyDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 15- PendingUse Of Aprepitant For Treating Alzheimer's DiseaseUSPTOApplication 18919118
- GrantedUse Of Aprepitant For Treating Alzheimer's DiseaseUSPTOUS 12,144,815
- PendingCompositions And Methods For Treating Lung InflammationUSPTOApplication 18016819
Show all 15 patent records
- Use Of Aprepitant For Treating Alzheimer's DiseaseJan 30, 2025 · Application 18919118Pending
- Use Of Aprepitant For Treating Alzheimer's DiseaseNov 19, 2024 · US 12,144,815Granted
- Compositions And Methods For Treating Lung InflammationNov 2, 2023 · Application 18016819Pending
- Nanohole Array Based Sensors With Various Coatings And Temperature Control For COVID-19Mar 10, 2022 · Application 17472277Pending
- Use Of Aprepitant For Weight LossApplication 63618522Pending
- Use Of Aprepitant For Treating Alzheimer's DiseaseApplication PCTUS2022017320Pending
- Nanohole Array Based Sensors With Various Coatings And Temperature Control For COVID-19Application PCTUS2021049908Pending
- Compositions And Methods For Treating Lung InflammationApplication PCTUS2021042063Pending
- Use Of Aprepitant For Treating Alzheimer's DiseaseApplication 63152458Pending
- Compositions And Methods For Treating Lung InflammationApplication 63053606Pending
- Topical Aprepitant FormulationApplication PCTUS2025042783Pending
- Use Of Aprepitant For Relieving Side Effects Associated With The Administration Of Weight Loss MedicationsApplication 19604042Pending
- Topical Aprepitant FormulationApplication 63750577Pending
- Use Of Aprepitant For Relieving Side Effects Associated With The Administration Of Weight Loss MedicationsApplication PCTUS2025010531Pending
- Topical Aprepitant FormulationApplication 63685456Pending
Related companies, and why
- Abeona Therapeutics LLCSimilar federal contract value in Biotech · null in contracts
- Prevail TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Carbon BiosciencesSimilar federal contract value in Biotech · null in contracts
- Cristcot LLCSimilar federal contract value in Biotech · null in contracts
- Angiex, Inc.Similar federal contract value in Biotech · null in contracts
- SpringWorks TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .